DMACHIGH SIGNALFINANCIAL10-K

DMAC significantly increased cash position to $15.6M (+417%) likely through equity financing, but operating losses deepened to -$32.8M as R&D spending accelerated.

The dramatic cash increase suggests successful fundraising that provides runway for continued operations, but came at the cost of substantial dilution (share count up 26%). The worsening cash burn rate of -$29.1M means the new capital may only provide 6-9 months of runway at current spending levels, creating near-term financing pressure.

Comparing 2026-03-30 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

DMAC's financial position shows a tale of two narratives - a massive 417% cash increase to $15.6M and 38% growth in stockholders' equity signals successful capital raising, but operating performance deteriorated significantly with losses widening 34% to -$32.8M and R&D expenses jumping 29% to $24.6M. The 26% increase in share count indicates the cash raise came through dilutive equity financing. With operating cash burn accelerating to -$29.1M, the company faces renewed funding pressures within 6-9 months despite the recent capital infusion.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+417.3%
$3.0M$15.6M

Cash position surged 417.3% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
+60%
$25K$40K

Capital expenditure jumped 60% — major investment cycle underway; assess returns on deployment.

Stockholders Equity
Balance Sheet
+37.8%
$40.7M$56.1M

Equity base grew 37.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+35.9%
$44.6M$60.6M

Current assets grew 35.9% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
-34%
-$24.4M-$32.8M

Net income declined 34% — review whether driven by operations, interest costs, or non-recurring items.

Total Assets
Balance Sheet
+32.4%
$46.3M$61.4M

Asset base grew 32.4% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-31.6%
-$22.1M-$29.1M

Operating cash flow fell 31.6% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+29.2%
$19.1M$24.6M

R&D investment increased 29.2% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-28.9%
-$26.7M-$34.4M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-17
ADDED
As of March 27, 2026, there were 53,882,506 voting common shares outstanding.
Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
Moreover, we operate in a highly competitive and rapidly-changing environment.
Business Overview We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS).
We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for PE, FGR and AIS.
+7 more — sign up free →
REMOVED
As of March 14, 2025, there were 42,855,660 voting common shares outstanding.
Moreover, we operate in a very competitive and rapidly-changing environment.
Business Overview We are a clinical stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE).
We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for AIS and PE.
Our lead candidate DM199 is a recombinant form of human tissue kallikrein-1 , which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and the first and only rhKLK1 undergoing global clinical development studies in both AIS and PE.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →